research Inappropriate Sexual Behaviors in Patients with Vascular Dementia: Possible Response to Finasteride
Finasteride may help reduce inappropriate sexual behaviors in dementia patients with prostate issues.
Search
for
Sort by
Research
450-480 / 1000+ results research Editorial Comment
PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.
research Mitigating Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Ameliorating Sexual Function and Psychological Well-Being in Older Men
Improving prostate and urinary health can enhance sexual function and mental well-being in older men.
research Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia
Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.
research This Month in Adult Urology
The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.
research Recent advances in treatment for Benign Prostatic Hyperplasia
BPH treatments are improving with personalized medicine and better surgical options.
research Role of 5α-reductase inhibitors in benign prostatic diseases
5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.
research MP13-07 FINASTERIDE MONOTHERAPY BEFORE TURP: SIGNIFICANT IMPROVEMENT IN EARLY POSTOPERATIVE QUALITY OF LIFE
Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
research The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction
Treatments for enlarged prostate can cause problems with ejaculation, and less invasive options might preserve sexual function better.
research Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients
Dutasteride reduces DHT more effectively than finasteride.
research The Benefits of Dual Inhibition of 5α Reductase
Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.
research Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial
Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
research Dutasteride for the treatment of benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
research Medikamentöse Therapie des benignen Prostatasyndroms mit α1-Rezeptorblockern Grundlagen und klinische Ergebnisse
Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.
research Editorial Comment
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
research Male Accessory Sex Glands
Male accessory sex glands in rats rarely develop tumors and respond to hormones.
research Morphological Changes of Meibomian Glands in Men With Benign Prostate Hyperplasia
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
research This Month in Clinical Urology
New treatments and diagnostic methods for urological conditions show promise, but some lack sufficient accuracy for clinical use.
research Intracavernous injection of platelet‐rich plasma reverses erectile dysfunction of chronic cavernous nerve degeneration through reduction of prostate hyperplasia evidence from an aging‐induced erectile dysfunction rat model
Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.
research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
research Low‐dose in utero exposure to finasteride promotes developmental changes in both male and female gerbil prostates
Exposure to low doses of finasteride in the womb causes changes in the prostate of both male and female gerbils.
research The preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice
Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
research Management of Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia During and After COVID-19
Doctors should adjust how they treat men with prostate-related urinary problems during and after the COVID-19 pandemic.
research The innervation of the mystacial pad in the adult rat studied by anterograde transport of HRP conjugates
The mystacial pad's innervation in adult rats is more complex than previously thought.
research Evaluation of residual symptoms and anxiety among patients on therapy for benign prostatic hyperplasia at a Nigerian tertiary healthcare facility
Many patients with benign prostatic hyperplasia experience high anxiety and residual symptoms, needing better anxiety management.
research MP45-12 CHRONIC ADMINISTRATION OF A LIMK2 INHIBITOR IMPROVES CAVERNOSAL VENO-OCCLUSIVE DYSFUNCTION THROUGH SUPPRESSION OF CAVERNOSAL FIBROSIS IN A RAT MODEL OF ERECTILE DYSFUNCTION AFTER CAVERNOSAL NERVE INJURY
Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
research Medical Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
Treatment for benign prostatic hyperplasia involves drugs that either quickly relieve symptoms or reduce prostate size, with a combination offering more benefits but more side effects.
research Association of Benign Prostatic Hyperplasia with Male Pattern Baldness
Men with enlarged prostates often have more severe baldness.
research The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.
research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.